Human recombinant interleukin-1 alpha is proinflammatory in normal human skin.
The proinflammatory effects of recombinant human interleukin-1 alpha (HRIL-1 alpha) have been determined in the skin of normal human volunteers. Intradermal injection of 10, 50 and 100 U HRIL-1 alpha produced dose-related erythema which first appeared at 2 h, was maximal around 24 h, persisted for up to 48 h, and was associated with oedema. Histological examination revealed dermal mononuclear cell infiltrates, which were accompanied by neutrophils at 4 and 8 h. Injection of heat-treated HRIL-1 alpha (100 U) produced no erythema or oedema. These results demonstrate the potent proinflammatory properties of HRIL-1 alpha in human skin.
Dowd
P M
PM
Institute of Dermatology, United Medical School, St. Thomas' Hospital, London, UK.
Camp
R D
RD
Greaves
M W
MW
D000328:Adult; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D003872:Dermatitis / Q000209:etiology / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007375:Interleukin-1 / Q000008:administration & dosage / Q000494:pharmacology*; D007958:Leukocyte Count; D008297:Male; D009504:Neutrophils / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012867:Skin / Q000473:pathology
D007375:Interleukin-1; D011994:Recombinant Proteins; D002097:C-Reactive Protein